Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTELLANCE 2: ABT-414 ± temozolomide vs lomustine or temozolomide for recurrent glioblastoma
2014-004438-24Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of depatuxizumab mafodotin in glioblastoma (GBM) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Overall survival and Progression-free survival (primary). Started May 2015; status: completed.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2014-004438-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004438-24.